Negative result in Tripep's phase II study
Negative result in Tripep's phase II study In the ongoing phase II study of GPG®, treatment has been completed on a total of 27 patients, and efficacy analyses have been performed. Only three patients meet the study's positive response criteria. The company state that in humans it has not been possible to reproduce the favorable HIV-inhibiting effect that has been achieved in test tubes. As a result of these findings the planned clinical program for GPG® is discontinued. Ten patients who are currently in the study will complete the study, and their efficacy data will be presented. The company will discuss with its Clinical Advisory Board whether additional patients will be included, enabling the entire study, comprising 45 patients, to be completed. In terms of safety profile, GPG® is very well tolerated. Tripep will now analyze the results in more detail in order to determine if there is a scientific basis for the continued development of GPG® for certain groups of HIV patients. We know that Tripep's researchers have identified a unique mechanism of action, for which the company has filed a patent application. The result of the study may have an impact on the development in two other PPI projects: TNF-alpha and the hepatitis C inhibiting agent. The company's six other preclinical projects are developing according to plan. The greatest progress has been made for the hepatitis C therapeutic vaccine and the drug for combating nosocomial (hospital acquired) infections. Since it is now unlikely that Tripep will be conducting phase III studies of GPG® under own management, approximately SEK 100 million has been released, and thus the company will not have any capital requirement in the coming three-year period. For further information, please contact: Hans Möller, President and CEO, tel. +46-8-449 84 80, mobile +46-708-15 16 89, e-mail: hans.moller@tripep.se. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/09/17/20010917BIT00020/bit0002.doc http://www.waymaker.net/bitonline/2001/09/17/20010917BIT00020/bit0002.pdf